论文部分内容阅读
目前,我国肺癌发病率与死亡率居高不下,其中非小细胞肺癌(NSCLC)约占肺癌总数的80%以上,死亡率也高达85%左右[1]。由于非小细胞肺癌在初诊时,约有50%左右的患者已出现胸腔外转移,10%~15%的患者初诊时已属局部晚期,错过手术时机[2]。我们观察并探讨了多西他赛联合顺铂治疗老年晚期NSCLC患者的临床疗效及安全性,现将结果报告如下。一、资料与方法1.一般资料:选取2010年1月至2012年12月间确诊
At present, the incidence and mortality of lung cancer are high in our country, of which non-small cell lung cancer (NSCLC) accounts for more than 80% of the total number of lung cancer and the mortality rate is as high as 85% [1]. As non-small cell lung cancer in the first visit, about 50% of patients have been extra-thoracic metastasis, 10% to 15% of patients have been newly diagnosed late, missed the timing of surgery [2]. We observed and discussed docetaxel combined with cisplatin in the treatment of elderly patients with advanced NSCLC clinical efficacy and safety, the results reported below. First, the data and methods 1 general information: selected from January 2010 to December 2012 confirmed